Mainz Biomed NV (MYNZ)
(Delayed Data from NSDQ)
$0.35 USD
-0.03 (-8.16%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $0.35 0.00 (0.29%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MYNZ 0.35 -0.03(-8.16%)
Will MYNZ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MYNZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MYNZ
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
MYNZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
What Makes Mainz Biomed NV (MYNZ) a New Buy Stock
Other News for MYNZ
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Mainz Biomed Provides Half Year 2024 Corporate Update
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Buy Rating Reiterated for Mainz Biomed B.V. on Strong ColoAlert Clinical Data Despite Market Pressures